ACRBP and neoplasm: Although the cellular immune response of OY‐TES‐1 in ovarian cancer has not yet been reported, liver cancer and lung cancer OY‐TES‐1 can induce specific cytotoxic T lymphocytes (CTLs) that led to specific tumor lethality.36, 37, 91